April 20, 2022

This study, published in the Journal of Pharmacology and Experimental Therapeutics, evaluates the response of both non-human primates and healthy human subjects to etavopivat. Etavopivat is a small molecule activator of the glycolytic enzyme erythrocyte pyruvate kinase. It is being developed to treat sickle cell disease (SCD) and is hypothesized to work via multiple mechanisms that increase...

Before the pandemic, Ohio offered in-person education for parents of children with sickle cell trait (SCT), a condition that afflicts about 8% of African Americans born each year. It was found that participating individuals with a low health literacy rate were less likely to achieve a suitable level of knowledge about managing SCT. This study,...

Sickle cell disease (SCD) is a chronic, autosomal, recessive disease caused by a mutation in hemoglobin’s beta chain that results in structural alterations to the red blood cell membrane, lowering its average lifespan and oxygen-carrying capacity. This study, published in Hematology, Transfusion, and Cell Therapy, sought to determine the impact of neuropathic pain on quality of life...

A successful transition from pediatric to adult care is crucial for adolescents and young adults (AYAs) living with sickle cell disease. Preparation for this transition is key to reducing the morbidity and mortality risks they could potentially face later in life. Researchers at the University of Missouri conducted a cross-sectional, correlational study to explore the...

It is considered best practice for kids with sickle cell anemia to receive antibiotic prophylaxis to prevent serious infections. Additionally, it is recommended that they undergo transcranial Doppler (TCD) screening to determine their risk of overt stroke. However, it remains unclear how many children with sickle cell anemia actually receive antibiotic prophylaxis and/or undergo TCD...